The center becomes the Marcus Center of Excellence for Cell Biomanufacturing
A second gift is received from the Marcus Foundation with the goal to enable Georgia Tech engineers to advance work at the center to develop automated bioreactor systems that eliminate the need for costly cleanrooms.
CMaT develops a course with the International Society for Cell and Gene Therapy at the Marcus Center
CMaT along with the ISCT produced a course that was created for hands-on training and key laboratory skill sets that are needed for CGT production.
CMaT is Renewed by the National Science Foundation
NSF renewed funding for CMaT, which aims to transform the manufacturing of cell-based therapeutics in a large-scale, low-cost, reproducible and high-quality process. The renewal is part of a $40 million award from the Marcus Foundation, which will support research in cell characterization and automated manufacturing of cell therapies.
NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT) begins
Led by the Georgia Institute of Technology, the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT) helps revolutionize the treatment of cancer, heart disease, autoimmune diseases and other disorders by enabling broad use of potentially curative therapies that utilize living cells – such as immune cells and stem cells – as “drugs.”
Cell Manufacturing Roadmap is created
An industry-driven consortium developed a national roadmap designed to chart the path to large-scale manufacturing of cell-based therapeutics for use in a broad range of illnesses including cancer, neuro-degenerative diseases, blood and vision disorders and organ regeneration and repair.
The Marcus Center for Therapeutic Cell Characterization and Manufacturing is established
The vision of making affordable, high-quality cell-based therapies available to hundreds of thousands of patients worldwide moved closer to reality with the dedication of a new cell manufacturing research facility at Georgia Tech.
National Cell Manufacturing Consortium is established
Established a collaborative public-private partnership that engages industry, academia, regulators, and other stakeholders in removing barriers to the advancement of the cell-manufacturing industry, thereby bringing new therapies and diagnostics to the healthcare market.